A Phase 4 interventional study of Fractional CO2 laser assisted drug delivery and Topical Corticosteroid (TCS) in Psoriasis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Cairo University · Phase 4, Interventional, and Treatment
Among 22 studies in Psoriasis by Cairo University — 6 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · Cairo University.
Among the 22 studies in Psoriasis by Cairo University, this one is the 13th largest by planned enrollment of the 20 interventional ones, is one of 5 that started in 2026, is one of 4 in phase 4, and was the 20th registered.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 32 is below the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →6 of the 22 studies in Psoriasis by Cairo University are open now, in 1 country. Each count lists the studies.
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2026.
Median enrollment 40 across the 20 interventional studies, 214 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Psoriasis by Cairo University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07919873Cairo UniversityEfficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail Psoriasis | 2027-02 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Among the 22 studies in Psoriasis by Cairo University, from their registry updates:
To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
fractional carbon dioxide (CO₂) laser-assisted delivery of topical corticosteroids will be done on palmoplantar psoriasis every 4 weeks
Device: Fractional CO2 laser assisted drug delivery
Application of topical corticosteroid alone in patients with palmoplantar psoriasis daily.
Drug: Topical Corticosteroid (TCS)
Sessions of fractional CO2 every 4 weeks with application of topical steroids
Also known as: fractional CO2 laser
Daily application of topical corticosteroids on palmoplantar psoriasis
Also known as: Topical steroids
Improvement in Palmoplantar Psoriasis Severity Index (ppPASI) by topical corticosteroids only vs fractional CO₂ laser-assisted delivery of topical corticosteroids
The primary outcome will be the change in the Palmoplantar Psoriasis Severity Index (ppPASI) score from baseline to the end of treatment (at Week 12). The ppPASI assesses disease severity based on erythema, scaling, and induration/infiltration of the palms and soles, in addition to the affected surface area. Scores range from 0 to 72, with higher scores indicating more severe disease. Treatment success: Achievement of ppPASI-50, ppPASI-75, and ppPASI-90 (≥50%, ≥75%, and ≥90% reduction from baseline).
Time frame: 3 month
Physician Global Assessment (PGA)
Clinical improvement will be assessed using the Physician Global Assessment for palmoplantar psoriasis. The PGA is a 5- or 6-point scale: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe (if using the 6-point scale)
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Feb 2027, 6 months later.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 6 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.